Home
6494 All Specialties
1559 Arthroplasty
641 Shoulder & Elbow
577 Osteoarthritis
575 Physical Therapy & Rehab
570 Spine
552 Sports Medicine
543 Trauma
412 General Orthopaedics
345 Foot & Ankle
295 Hand & Wrist
198 Cannabis
88 Pediatric Orthopaedics
79 Metabolic Disorders
29 Peri-Operative
29 Tumour
2 Evidence Based Medicine

Conference Reports

Summaries of the best evidence presented at major orthopaedic conferences around the world.

Exclusive Interviews

Original authors are interviewed to verify the veracity of the ACE Report and provide additional information regarding the study’s findings and methodology.

PeerView

Features the top trending OE Content from your network over the past 30 days.

OE Originals
OE Insights
Videos
OE Plus
148 COVID 19 Resource Center
7 Ace Reviews
1 OE Recommends
6 OE PeerView
78 OE Ideas
24 OE World Tour
63 OE Perspectives
48 Conference ACE Reports
159 Exclusive Interviews
CME

To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:3 Number:12 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
Author Verified
RCT
ACE Report #4343
Ace Report Cover Tumour

Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy

How to Cite

OrthoEvidence. Osteosarcoma: 25 year survival rate significantly improved with adjuvant chemotherapy. ACE Report. 2013;2(3):12. Available from: https://myorthoevidence.com/AceReport/Report/4343

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma

Cancer. 2012 Dec 1;118(23):5888-93

Contributing Authors:
NM Bernthal N Federman FR Eilber SD Nelson JJ Eckardt FC Eilber WD Tap

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

59 patients who underwent treatment for stage IIA/IIB, intramedullary, high-grade osteosarcoma, between 1981 and 1984, were randomized to receive either T-10B protocol adjuvant chemotherapy or no adjuvant chemotherapy following definitive surgical resection. Improvements in disease-free survival (DFS) and overall survival (OS) were monitored over 25 years, and tumor necrosis was evaluated for impl...

To view the full content, login to your account,
or start your 30-day FREE Trial today.

FREE TRIAL Forgot Password?

Explore some of our unlocked ACE Reports below!

 Treatment of osteoarthritis: A role for education programmes?
The prevalence of intimate partner violence in women presenting to orthopaedic clinics
Osteoporosis Choice decision aid improves treatment experience of clinicians and patients
Protein-Rich nutritional supplementation shows limited efficacy in elderly hip fractures
Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.